Resultados de Búsqueda
Atezolizumab is recommended as an option for treating locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults who have had chemotherapy (and targeted treatment if they have an ...
NICE
National Institute for Health and Clinical Excellence (NICE)
Treatments for NSCLC after chemotherapy include docetaxel alone, pembrolizumab (for tumours expressing the PD‑L1 protein) and nintedanib plus docetaxel for adenocarcinoma. Clinical trial evidence shows that people having atezolizumab live longer than those having docetaxel alone. There is no evidence directly comparing atezolizumab with pembrolizumab. But indirect analyses show that for people with PD‑L1‑positive disease, there may be no difference in survival benefit for atezolizumab ...
ver más ... 2018Pembrolizumab is recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy
NICE
National Institute for Health and Clinical Excellence (NICE)
Treatment for previously treated locally advanced or metastatic urothelial carcinoma is docetaxel or paclitaxel. Clinical trial evidence shows that pembrolizumab significantly improves overall survival compared with these drugs. Pembrolizumab meets NICE's criteria to be considered a life-extending treatment at the end of life. The most plausible cost-effectiveness estimate is uncertain because it is not clear which overall survival extrapolation is most appropriate to use for the economic ...
ver más ... 2018Avelumab is recommended as an option for treating metastatic Merkel cell carcinoma in adults, only if they have had 1 or more lines of chemotherapy for metastatic disease.
NICE
National Institute for Health and Clinical Excellence (NICE)
Treatment options for metastatic Merkel cell carcinoma are limited. People are usually offered chemotherapy or best supportive care. Avelumab could potentially be used as a first-line treatment or after chemotherapy. Clinical trial evidence suggests that avelumab may improve overall survival compared with chemotherapy. But chemotherapy has not been compared directly with avelumab so the results are highly uncertain. The evidence on avelumab is promising, but the trial included only a small ...
ver más ... 2018Eribulin is not recommended for treating locally advanced or metastatic breast cancer in adults who have had only 1 chemotherapy regimen.
NICE
National Institute for Health and Clinical Excellence (NICE)
People with advanced breast cancer who have had 1 chemotherapy regimen are usually then offered an anthracycline, a taxane or capecitabine, depending on what they have had already. The clinical trial results for eribulin showed that it did not increase progression-free survival, but there was an average overall survival increase of 4.6 months compared with capecitabine. Since treatment is changed when the disease progresses, and eribulin would have been stopped at that stage, it is not clear ...
ver más ... 2018Pertuzumab, in combination with trastuzumab and docetaxel, is recommended, within its marketing authorisation, for treating HER2‑positive metastatic or locally recurrent unresectable breast cancer, ...
NICE
National Institute for Health and Clinical Excellence (NICE)
This recommendation is for a drug that has been available on the Cancer Drugs Fund for several years and the committee recognised this as an exceptional circumstance. In this context, the committee considered it reasonable to apply flexibility in its interpretation of the criteria for special consideration as a life-extending treatment for people with a short life expectancy, but noted that the weight applied to the quality-adjusted life years gained would not be at the maximum allocated in ...
ver más ... 2018